Manogepix is an investigational drug.
There have been 4 clinical trials for Manogepix.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 15th 2019.
The most common disease conditions in clinical trials are Mycoses, Invasive Fungal Infections, and Infection. The leading clinical trial sponsors are Amplyx Pharmaceuticals, Pfizer, and [disabled in preview].
There is one US patent protecting this investigational drug and thirty-three international patents.